首页> Cancer research> Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Howard I,Scher

第一单位： Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. scherh@mskcc.org.;Department of Medicine, Weill Cornell Medical College, New York, New York.

作者： Howard I,Scher ^[1] ; Ryon P,Graf ^[2] ; Nicole A,Schreiber ^[3] ; Brigit,McLaughlin ^[3] ; Adam,Jendrisak ^[2] ; Yipeng,Wang ^[2] ; Jerry,Lee ^[2] ; Stephanie,Greene ^[2] ; Rachel,Krupa ^[2] ; David,Lu ^[2] ; Pascal,Bamford ^[2] ; Jessica E,Louw ^[2] ; Lyndsey,Dugan ^[2] ; Hebert A,Vargas ^[4] ; Martin,Fleisher ^[5] ; Mark,Landers ^[2] ; Glenn,Heller ^[6] ; Ryan,Dittamore ^[2]

作者单位： Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. scherh@mskcc.org.;Department of Medicine, Weill Cornell Medical College, New York, New York. ^[1] Epic Sciences, La Jolla, California. ^[2] Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[3] Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. ^[4] Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[5] Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. ^[6]